K-V Pharmaceutical Enters Bankruptcy, Citing Makena Reimbursement Hurdles

K-V Pharmaceutical Enters Bankruptcy, Citing Makena Reimbursement Hurdles

NEW YORK - K-V Pharmaceutical Co. on Aug. 4 filed a voluntary Chapter 11 bankruptcy petition in the U.S. Bankruptcy Court for the Southern District of New York, saying its inability to market its controversial Makena premature labor drug have made it impossible to meet a milestone payment to the companies it bought the drug from and that was due Aug. 4 (In Re: K-V Pharmaceutical Company, No. 12-13347, E.D. N.Y. Bkcy.). View related prior history, 2012 U.S. Dist. LEXIS 62161.

Find full version on lexis Advance®
Access this news story on lexis.com®